BOSTON , Sept. 22, 2025 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, today announced an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) from the World CB & CDx Summit in Boston. The companies aim to improve the diagnosis and treatment of breast and prostate cancer by developing an optimized next generation sequencing (NGS) solution that leverages... Read More

BOSTON and ROLLE, Switzerland , Sept. 5, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, has announced a significant new collaboration with Jessa Ziekenhuis in Hasselt, Belgium . The institutions will partner to bring cutting edge genomic testing and oncology research to cancer patients across Belgium . Jessa Ziekenhuis, one of... Read More

BOSTON and ROLLE, Switzerland , Aug. 5, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the second quarter ended June 30, 2025 . Second Quarter 2025 Financial Results Revenue was $18.3 million , up 16% year-over-year Gross margin was 67.0% on a reported basis and 74.4% on an adjusted basis, up from 68.2% reported and... Read More

BOSTON and ROLLE, Switzerland , Aug. 5, 2025 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an expansion of its partnership with AstraZeneca (LSE/STO/Nasdaq: AZN). This new, multi-year collaboration will leverage SOPHiA GENETICS's multimodal AI Factories to generate evidence on the efficacy, value, and real-world impact of... Read More

BOSTON and ROLLE, Switzerland , July 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the second quarter 2025 before U.S. markets open on Tuesday, August 5, 2025 . On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning... Read More

BOSTON and ROLLE, Switzerland , May 6, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2025 . First Quarter 2025 Financial Results Revenue was $17.8 million , up 13% year-over-year or 15% on a constant currency basis Gross margin was 68.7% on a reported basis and 75.7% on an adjusted... Read More

BOSTON and ROLLE, Switzerland , April 28, 2025 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and global leader in data-driven medicine, today announced the expansion of its ongoing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to accelerate the deployment of MSK-ACCESS® powered with SOPHiA DDM™ globally. Building on the initial collaboration announced in October 2024 , this new... Read More

BOSTON and ROLLE, Switzerland , April 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the first quarter 2025 before U.S. markets open on Tuesday, May 6, 2025 . On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at... Read More

The partnership integrates advanced AI-driven analytics and clinical trial solutions, empowering biopharma companies to accelerate drug development and deliver targeted therapies faster. BETHESDA, Md. and BOSTON and ROLLE, Switzerland , April 8, 2025 /PRNewswire/ -- Precision for Medicine, a leading provider of drug development and commercialization services, today announced a strategic partnership with SOPHiA GENETICS to... Read More

BOSTON, MA and ROLLE, Switzerland , March 18, 2025 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH) , a cloud-native software company and leader in data-driven medicine, has reached a historic milestone: more than two million patients genomic profiles analyzed on the AI-powered analytics Platform SOPHiA DDM™. This achievement solidifies SOPHiA GENETICS as the gold-standard provider of actionable insights for patient care, applying AI... Read More

BOSTON and ROLLE, Switzerland , March 4, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for its fourth quarter and fiscal year ended December 31, 2024 . Fourth Quarter 2024 Financial Highlights Revenue was $17.7 million , up 4% year-over-year or 6% on a constant currency basis excluding COVID-19-related revenue Gross... Read More

SOPHiA GENETICS enables institutions across the globe to launch world-class oncology testing BOSTON, MA and ROLLE, Switzerland , Feb. 24, 2025 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a pioneer in AI healthcare technology and a leader in data-driven medicine, announced a new milestone in the global adoption of its groundbreaking cancer testing applications MSK-ACCESS ® powered with SOPHiA DDM™ and MSK-IMPACT ® powered with... Read More

BOSTON and ROLLE, Switzerland , Feb. 18, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the fourth quarter and full year 2024 before U.S. markets open on Tuesday, March 4, 2025 . On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business... Read More

The cutting-edge OncoPortal™ Mutation Tracker add-on module enables precision monitoring of evolving genomic cancer drivers BOSTON, MA and ROLLE, Switzerland , Jan. 28, 2025 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, has unveiled the OncoPortal™ Mutation Tracker — a longitudinal MRD tracking tool designed for disease monitoring in the... Read More

Launch of new application enables global access to highly recognized solid tumor profiling assay BOSTON and ROLLE, Switzerland , Nov. 21, 2024 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology leader in data-driven medicine, announced the global launch of MSK-IMPACT ® powered with SOPHiA DDM™ today from the Association for Molecular Pathology (AMP) Annual Meeting. This innovative solution provides... Read More

The companies expand partnership to enhance genetic variant interpretation for cancers and rare diseases BOSTON and ROLLE, Switzerland , Nov. 6, 2024 /PRNewswire-PRWeb/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology leader in data-driven medicine, today announced the next step in the partnership between the Company and Genomenon, a leading genomic intelligence company, to support better, data-driven... Read More

BOSTON and ROLLE, Switzerland , Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today announced that Ross Muken , previously Chief Financial Officer ("CFO") and Chief Operating Officer ("COO"), has been promoted to company President, effective... Read More

Clinical growth reaccelerates with record analysis volume; Cash burn improves 39% BOSTON and ROLLE, Switzerland , Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the third quarter ended September 30, 2024 . Third Quarter 2024 Financial Results Revenue was $15.9 million , down 2.8% year-over-year Gross margins... Read More

BOSTON and ROLLE, Switzerland , Oct. 22, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the third quarter of fiscal year 2024 before U.S. markets open on Tuesday, November 5, 2024 . On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business... Read More

Research highlights the use of multimodal machine learning to identify non-small cell lung cancer patients predicted to derive the most benefit from combination immunotherapy BOSTON and ROLLE, Switzerland , Sept. 14, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, will unveil new research at the European Society for Medical Oncology... Read More

Research presented will include the applications of new diagnostic tools and machine learning multimodal signatures in clinical trials BOSTON and ROLLE, Switzerland , Sept. 12, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, will be presenting multiple posters at the European Society for Medical Oncology (ESMO) Congress 2024 being... Read More

The global collective intelligence network aims to accelerate precision oncology research and care BOSTON and ROLLE, Switzerland , Sept. 12, 2024 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an update that several world-renowned healthcare organizations have joined SOPHiA UNITY . SOPHiA UNITY is the global consortium... Read More

The companies commit to bring cutting-edge liquid biopsy testing to 20 institutions globally over the next 12 months BOSTON and ROLLE, Switzerland , Sept. 10, 2024 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a new milestone in the global introduction of the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™, first... Read More

The companies share how their collaboration enables clinical trial enrollment for a novel cancer therapy for oncogene amplified cancers in development by Boundless Bio BOSTON and ROLLE, Switzerland , Sept. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an update from the Company's work with biopharma company... Read More

New generation of SOPHiA DDM TM integrates latest advancements in data processing and technology to deliver elevated experience and capabilities to customers BOSTON and ROLLE, Switzerland , Sept. 4, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today launched the new generation of the SOPHiA DDM TM Platform. The new-gen SOPHiA... Read More

BOSTON and ROLLE, Switzerland , Aug. 28, 2024 /PRNewswire/ -- SOPHiA GENETICS , a cloud-native software company and a leader in data-driven medicine, today announced presentations at the 22 nd Annual Morgan Stanley Healthcare Conference and the 9 th Annual TD Cowen FutureHealth Conference in early September. Chief Financial Officer and Chief Operating Officer, Ross Muken , will present at the 22 nd Annual Morgan Stanley... Read More

Regulatory milestone validates the SOPHiA DDM™ Platform as diagnostic tool in select markets BOSTON and ROLLE, Switzerland , Aug. 14, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that its SOPHiA DDM™ Platform is now CE marked under the European Union's In Vitro Diagnostic Regulation (IVDR). IVDR certification is... Read More

Strength in U.S. Growth Offset by Challenges in BioPharma and EMEA; Strong Cost Management Buffers Loss BOSTON and ROLLE, Switzerland , Aug. 6, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the second quarter ended June 30, 2024 . Second Quarter 2024 Financial Update Revenue was $15.8 million , up 5%... Read More

The hospital will use the SOPHiA DDM™ Platform to enhance its testing and research of blood cancers BOSTON and ROLLE, Switzerland , July 29, 2024 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, today announced that L'hôpital Universitaire Avicenne is implementing the SOPHiA DDM™ Platform. The hospital, located in Bobigny, France , will use the... Read More

OncoHelix is the first laboratory in Canada to adopt MSK-ACCESS ® powered with SOPHiA DDM™ BOSTON and ROLLE, Switzerland , July 24, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today that OncoHelix, an internationally recognized research and diagnostics laboratory for precision diagnostics, will implement MSK-ACCESS ® powered... Read More

BOSTON and ROLLE, Switzerland , July 23, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the second quarter of fiscal year 2024 before U.S. markets open on Tuesday, August 6, 2024 . On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business... Read More

The diagnostics company has implemented the SOPHiA DDM™ Platform to enhance its solid tumor testing BOSTON and ROLLE, Switzerland , July 4, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India , is live on the SOPHiA DDM™ Platform.... Read More

BOSTON and ROLLE, Switzerland, June 24, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a healthcare technology company and a leader in data-driven medicine, is pleased to announce that its annual general meeting of shareholders (the “ AGM ”) was held at the Company’s headquarters, La Piece 12, 1180 Rolle/VD, Switzerland, earlier today at 14:00 CEST (8:00 a.m. EDT). The Company’s shareholders have adopted all... Read More

Novel application supports measurable residual disease (MRD) testing to help monitor cancer and stay ahead of relapse BOSTON and ROLLE, Switzerland , June 24, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced its new Residual Acute Myeloid (RAM) Application. The new offering expands the company's comprehensive... Read More

The Hospital will use SOPHiA DDM™ to enhance its testing and research of blood cancers BOSTON and ROLLE, Switzerland , June 13, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, today announced that Kepler Uniklinikum, Austria's second largest hospital, is live on SOPHiA GENETICS' platform. The hospital will use the SOPHiA DDM™ Platform to... Read More

New collective intelligence network to enable the most advanced research in oncology in support of precision medicine BOSTON and ROLLE, Switzerland , May 30, 2024 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced SOPHiA UNITY, a new data-driven consortium designed to accelerate cancer research globally. SOPHiA UNITY aims to bring... Read More

In collaboration with Microsoft and NVIDIA, SOPHiA GENETICS is developing a comprehensive whole genome analytical solution BOSTON and ROLLE, Switzerland , May 29, 2024 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that it is collaborating with Microsoft and NVIDIA to leverage their expertise in technology and genomics to... Read More

The hospital will enhance its testing and research of blood cancers with the SOPHiA DDM™ Platform BOSTON and ROLLE, Switzerland , May 20, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Instituto Mário Penna is live on the SOPHiA DDM™ Platform. Located in Belo Horizonte, Brazil , the Instituto Mário Penna will... Read More

The SOPHiA DDM™ Platform will help broaden the hospital's cancer testing and diagnostic capabilities BOSTON and ROLLE, Switzerland , May 16, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Klinikum Klagenfurt am Wörthersee, the third largest hospital in Austria , is live on the SOPHiA DDM™ Platform. The hospital will use SOPHiA... Read More

BOSTON and ROLLE, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Highlights Revenue grew 13% year-over-year to $15.8 million; Constant currency revenue excluding COVID-related revenue grew 12% year-over-year Gross margins... Read More

BOSTON and ROLLE, Switzerland, April 30, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS , a cloud-native software company and a leader in data-driven medicine, today announced that Chief Financial Officer and Chief Operating Officer, Ross Muken, will present at the 2024 RBC Capital Markets Global Healthcare Conference in New York City on Tuesday, May 14, 2024, at 3:35 p.m. EDT. The presentation will be webcast live on the SOPHiA... Read More

BOSTON and ROLLE, Switzerland, April 23, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS , a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the first quarter of fiscal year 2024 before U.S. markets open on Tuesday, May 7, 2024. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning... Read More

Syndicate Bio to implement new liquid biopsy offering to advance cancer diagnostics throughout Africa BOSTON and ROLLE, Switzerland , April 23, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Nigeria -based... Read More

European-based Unilabs has deployed the SOPHiA DDM™ Platform across its network in Switzerland to support cancer diagnostics and treatment BOSTON and ROLLE, Switzerland , April 17, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Unilabs, one of the largest diagnostic providers in Europe , and the only provider to offer laboratory,... Read More

The companies will join forces to advance the use of precision medicine on a global scale BOSTON and ROLLE, Switzerland , April 4, 2024 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced a strategic partnership with Strand Life Sciences, a pioneer in bioinformatics and diagnostics, to deliver innovative solutions that will... Read More

The Chile -based Laboratory is using SOPHiA GENETICS' platform to advance its research capabilities with blood disorders BOSTON and ROLLE, Switzerland , April 2, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Laboratorio Barnafi-Krause is live on the SOPHiA DDM™ Platform. Laboratorio Barnafi-Krause, located in Chile , has... Read More

University of Saskatchewan's (USask) Advanced Diagnostics Research Laboratory will use SOPHiA DDM™ Platform to advance research on ovarian cancer care BOSTON and ROLLE, Switzerland , March 20, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced the University of Saskatchewan (USask) as its first HRD customer in Canada . USask will... Read More

New Multimodal Algorithm Highlights Predictive Benefit Of Artificial Intelligence (AI) for Cancer Research BOSTON and ROLLE, Switzerland , March 15, 2024 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, and the French Kidney Cancer Research Network (UroCCR) collaborated on a study using a multimodal algorithm to help predict post-operative outcomes for those... Read More

BOSTON and ROLLE, Switzerland, March 07, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced Chief Financial Officer and Chief Operating Officer, Ross Muken, will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13, 2024, at 2:35 p.m. EDT. The fireside chat will be webcast live... Read More

BOSTON and ROLLE, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today reported financial results for its fourth quarter and fiscal year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights Revenue grew 27% year-over-year to $17.0 million; Constant currency revenue excluding COVID-related revenue also grew 27%... Read More

BOSTON and ROLLE, Switzerland, Feb. 22, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced Co-founder and Chief Executive Officer, Dr. Jurgi Camblong, and Chief Financial Officer and Chief Operating Officer, Ross Muken, will participate in a fireside chat at the 44th Annual TD Cowen Health Care Conference on Wednesday, March 6, 2024,... Read More

BOSTON and ROLLE, Switzerland, Feb. 20, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the fourth quarter and full-year 2023 before U.S. markets open on Tuesday, March 5, 2024. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business... Read More

SOPHiA GENETICS and AstraZeneca Spain expand HRD testing program to support molecular diagnosis of ovarian cancer in Spain BOSTON and ROLLE, Switzerland and MADRID , Feb. 7, 2024 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it has expanded an existing program in Spain to increase access to local testing for homologous recombination deficiency... Read More

The company announced Bioma4me has implemented SOPHiA DDM™ to support its rare disorder testing capabilities BOSTON and ROLLE, Switzerland , Jan. 25, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Bioma4me, a Brazil -based company focused on genetic sequencing to drive precision medicine to the Brazilian... Read More

RareCyte will use the SOPHiA DDM™ Platform to support its oncology testing panel BOSTON and ROLLE, Switzerland , Jan. 18, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that RareCyte Inc., a precision biology company based in Seattle, Washington , is live on SOPHiA GENETICS. RareCyte has implemented the SOPHiA DDM™ Platform to... Read More

SOPHiA GENETICS technology helps advance cancer research across India SOPHiA GENETICS and Karkinos Healthcare join forces to propel cutting-edge genomic solutions for breakthroughs in personalized cancer care in India BOSTON and ROLLE, Switzerland , Jan. 14, 2024 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Karkinos Healthcare, a... Read More

Strong SOPHiA DDM™ adoption and analysis volume contributes to continued revenue growth Liquid biopsy and HRD on SOPHiA DDM™ Platform continue to grow year-over-year, with Tennessee Oncology, Dasa and The Royal Marsden announced today BOSTON and ROLLE, Switzerland , Jan. 10, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, will share an overview of its... Read More

Insights from multimodal datasets on the platform fuel cancer research in Canada BOSTON and ROLLE, Switzerland , Jan. 8, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced a collaboration with Exactis Innovation, based in Montreal, Quebec , who will contribute to cancer research and data-driven decision-making through SOPHiA GENETICS'... Read More

The Hospital will use SOPHiA GENETICS technology to streamline workflows and expedite research BOSTON and ROLLE, Switzerland , Dec. 21, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Hôpital Saint-Louis , located in Paris , has implemented the SOPHiA DDM™ Platform to help advance its research of Myeloid Disorders and continue... Read More

BOSTON and ROLLE, Switzerland, Dec. 14, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (NASDAQ: SOPH) today announced that Jurgi Camblong, PhD., Chief Executive Officer and Co-founder, is scheduled to present at the J.P. Morgan 2024 Healthcare Conference on Thursday, January 11, 2024, at 9:00 a.m. PST in San Francisco. Live, listen-only webcasts of this presentation can be accessed by visiting the Investors section of the SOPHiA... Read More

World-class liquid biopsy testing will be available to SOPHiA GENETICS customers BOSTON and ROLLE, Switzerland , Dec. 7, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced an expanded suite of solutions under SOPHiA DDM™ for Liquid Biopsy. The range of solutions, including MSK-ACCESS® powered with SOPHiA DDM™ and custom solutions, will... Read More

Through the expanded relationship CHU de Nîmes will advance its research of rare and inherited diseases through pharmacogenomics BOSTON and ROLLE, Switzerland , Nov. 30, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that it has expanded its work with CHU de Nîmes, a regional and university hospital located in the South of France.... Read More

Largest health center in Italy uses SOPHiA DDM™ Platform on Microsoft Azure to expand data-driven medicine capabilities while ensuring accuracy and security BOSTON and ROLLE, Switzerland , Nov. 28, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced the expansion of its relationship with the Città della Salute e... Read More

The SOPHiA DDM™ Platform used by IHG PAS to advance its research of male infertility BOSTON and ROLLE, Switzerland , Nov. 17, 2023 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that the Institute of Human Genetics, Polish Academy of Sciences (IHG PAS), the leading center for genetics research in Poland , is now live on the SOPHiA DDM™ Platform.... Read More

World-class liquid biopsy testing will be made commercially available to BioReference® customers across the country BOSTON and ELMWOOD PARK, N.J. , and ROLLE, Switzerland , Nov. 7, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that BioReference ® Health, LLC, an OPKO Health, Inc. company and full-service laboratory that processes... Read More

BOSTON and ROLLE, Switzerland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today reported financial results for the third quarter ended September 30, 2023. Recent Highlights Revenue for the third quarter of 2023 was $16.3 million, representing year-over-year growth of 40% on a reported basis over the corresponding period of 2022;... Read More

BOSTON and GENEVA, Switzerland, Oct. 24, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the third quarter of fiscal 2023 before U.S. markets open on Tuesday, November 7, 2023. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business... Read More

The three companies will collaborate to improve global access to advanced cancer testing and data, broadening access to cutting-edge science BOSTON and ROLLE, Switzerland , Oct. 18, 2023 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a category-defining software company and a global leader in data-driven medicine today announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK), a top cancer treatment and research... Read More

The hospital will use the SOPHiA DDM™ Platform to further its work with myeloid disorders and advance the development of precision medicine BOSTON and ROLLE, Switzerland , Sept. 29, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Shaare Zedek, the largest multi-disciplinary medical center in Jerusalem , is now live on the SOPHiA... Read More

The SOPHiA DDM™ Platform will help Laboratorio Curie advance its research into BRCA gene mutations BOSTON and ROLLE, Switzerland , Sept. 13, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, has expanded its relationship with Laboratorio Curie, a leading laboratory located in the capital city of Paraguay . Laboratorio Curie is now live on the SOPHiA... Read More

With the help of the SOPHiA DDM™ Platform, IRST has introduced a new diagnostic kit that will support data-driven treatment planning for advanced ovarian cancer BOSTON and ROLLE, Switzerland , Sept. 7, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, is helping excel the use of precision medicine to treat advanced ovarian cancer. The company today... Read More

The hospital is using the SOPHiA DDM™ Platform to advance the research of Homologous Recombination Repair Mutated Cancers BOSTON and ROLLE, Switzerland , Aug. 30, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that CHU Bordeaux, a full-service hospital servicing the population of Bordeaux and the surrounding area, has completed... Read More

Gustave Roussy uses SOPHiA DDM™ Platform to empower confident, data-driven medicine in the fight against cancer BOSTON and ROLLE, Switzerland , Aug. 22, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced the expansion of its relationship with Gustave Roussy, the leading cancer center in Europe . With the expanded... Read More

The Hospital will use the SOPHiA DDM™ Platform to advance its research and diagnosis of blood cancers BOSTON and ROLLE, Switzerland , Aug. 17, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that A.O.U. San Giovanni di Dio Ruggi d'Aragona is now utilizing the SOPHiA DDM™ Platform to advance its research and diagnosis of blood cancers,... Read More

BOSTON and ROLLE, Switzerland, Aug. 08, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today reported financial results for the second quarter ended June 30, 2023. Recent Highlights Revenue for the second quarter of 2023 was $15.1 million, representing year-over-year growth of 29% on a reported basis over the corresponding period of 2022;... Read More

The School of Medicine will use the SOPHiA DDM™ Platform to expand its hematologic testing program for blood cancers BOSTON and ROLLE, Switzerland , Aug. 8, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that the Tulane University School of Medicine in New Orleans, Louisiana is live on SOPHiA GENETICS technology. The 15 th oldest... Read More

BOSTON and ROLLE, Switzerland , July 25, 2023 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced it will release its financial results for the second quarter of fiscal 2023 before U.S. markets open on Tuesday, August 8, 2023 . On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning... Read More

CSM is using the SOPHiA DDM™ Platform to expand its next-generation sequencing (NGS) offering s BOSTON and ROLLE, Switzerland , July 13, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced Gruppo Centro Servizi Medici (CSM), one of the largest centralized laboratories in Italy , is live on SOPHiA GENETICS technology. CSM has implemented... Read More

SOPHiA DDM™ Platform will bring next-generation sequencing in-house and help further research on hematologic malignancies BOSTON and ROLLE, Switzerland , July 7, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced Centre Hospitalier de Bastia is live on the SOPHiA DDM™ Platform. Centre Hospitalier de Bastia, a general hospital located in... Read More

BOSTON and ROLLE, Switzerland , June 26, 2023 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, is pleased to announce that its Annual General Shareholders Meeting (the "AGM ") was held at the Company's new headquarters, La Piece 12, 1180 Rolle VD, Switzerland , earlier today at 14:00 CEST ( 8:00 a.m. EDT ). The Company's... Read More

SOPHiA GENETICS technology to aid research associated with hereditary cancers and disorders BOSTON and LAUSANNE, Switzerland , June 22, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Ankara Etlik City Hospital, the largest hospital in the capital city of Turkey , is live on the SOPHiA DDM™ Platform. The... Read More

SOPHiA GENETICS technology aids NOMAD Genetics in the advancement of its cancer research capabilities BOSTON and LAUSANNE, Switzerland , June 15, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced a strategic alliance with NOMAD Genetics . Headquartered in Mexico City and Chile , NOMAD is an innovative laboratory... Read More

As a leader in data-driven medicine , SOPHiA GENETICS lends its expertise to support White House Cancer Moonshot BOSTON and LAUSANNE, Switzerland , June 2, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, announced today at ASCO that it has joined as a founding member of CancerX , a new public-private partnership formed to... Read More

Microsoft's Deputy Chief Technology Officer to be appointed at Annual Shareholders' Meeting BOSTON and LAUSANNE, Switzerland , May 31, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced the nomination of Lila Tretikov to its Board of Directors. The Board of Directors has proposed the appointment of Tretikov as a... Read More

SOPHiA DDM™ deep-learning algorithm will help determine HRD status of tumors for Institute of Oncology Ljubljana researchers BOSTON and LAUSANNE, Switzerland , May 24, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that the Institute of Oncology Ljubljana (IOL), a comprehensive public institution for detection,... Read More

SOPHiA GENETICS technology will help increase cancer research abilities BOSTON and LAUSANNE, Switzerland , May 16, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Natural State Laboratories , a xfull-service, state-of-the-art molecular laboratory based in Little Rock, Arkansas , has chosen SOPHiA GENETICS... Read More

In just one year of using SOPHiA DDM™ HRD, Dasa reaches 2,000 samples analyzed BOSTON and LAUSANNE, Switzerland , May 8, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and the leader in data-driven medicine, celebrates today with longstanding partner, Dasa, the largest integrated healthcare network in Brazil , as it reaches a milestone of 2,000 samples analyzed for HRD status. This... Read More

BOSTON and LAUSANNE, Switzerland, May 09, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today reported financial results for the first quarter ended March 31, 2023. Recent Highlights Revenue for the first quarter of 2023 was $14.0 million, representing year-over-year growth of 29% on a reported basis over the corresponding period of 2022; Constant... Read More

SOPHiA GENETICS expands footprint in India as Unipath Specialty Laboratory Limited is now live on SOPHiA DDM™ HRD Solution BOSTON & LAUSANNE, Switzerland / May 03, 2023 / Business Wire / SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Unipath Specialty Laboratory Limited, one of the leading diagnostic brands in India, is live... Read More

Recognition by the Swiss Biotech Association for SOPHiA GENETICS’ Outstanding Contributions as a Leader in Data-Driven Medicine BOSTON & LAUSANNE, Switzerland / Apr 25, 2023 / Business Wire / SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, was honored to accept the Swiss Biotech Success Stories Award from the Swiss Biotech Association. The Award... Read More

BOSTON and GENEVA, Switzerland, April 25, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced it will release its financial results for the first quarter of fiscal 2023 before U.S. markets open on Tuesday, May 9, 2023. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at... Read More

SOPHiA GENETICS supports The University of Maryland Medical Center to advance their rare disease research BOSTON & LAUSANNE, Switzerland / Apr 18, 2023 / Business Wire / SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that the University of Maryland Medical Center (UMMC) is using SOPHiA GENETICS technology to enhance their... Read More

SOPHiA DDM™ for Hereditary Cancers Enables Krsnaa Diagnostics to Expand its NGS Offerings BOSTON & LAUSANNE, Switzerland / Apr 11, 2023 / Business Wire / SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Krsnaa Diagnostics, India’s largest diagnostic services provider in radiology and pathology, is live on SOPHiA DDM™ technology.... Read More

SOPHiA DDM TM HRD Solution will help empower clinical researchers to advance cancer research BOSTON & LAUSANNE, Switzerland / Apr 04, 2023 / Business Wire / SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Tel Aviv Sourasky Medical Center (Ichilov), the largest acute care facility in Israel, has chosen to use SOPHiA DDM™ to... Read More

The New Assay Will Screen Patients for Clinical Trials and Help Increase Data Analysis for Clinical Researchers BOSTON & LAUSANNE, Switzerland / Mar 28, 2023 / Business Wire / SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Acutis Diagnostics, a specialized medical laboratory, will use SOPHiA DDM™ to develop a new genomic... Read More

BOSTON & LAUSANNE, Switzerland / Mar 14, 2023 / Business Wire / SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and the leader in data-driven medicine, is partnering with Agilent to offer a comprehensive solution for cancer analysis. Through the partnership, the SOPHiA DDM TM Platform will be integrated with Agilent’s new Research Use Only SureSelect Cancer Comprehensive Genomic... Read More

BOSTON & LAUSANNE, Switzerland / Mar 06, 2023 / Business Wire / SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and the leader in data-driven medicine, today announced the University of Arkansas for Medical Sciences (UAMS), based in Little Rock, AR, will use SOPHiA GENETICS’ platform to support their clinical oncology research. Beginning this year, UAMS will implement the SOPHiA DDM™ platform to gain deeper... Read More

BOSTON & LAUSANNE, Switzerland / Mar 03, 2023 / Business Wire / SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, has been named to Fast Company ’s prestigious annual list of the World’s Most Innovative Companies for 2023. This year’s list highlights the businesses at the forefront of their respective industries, paving the way for the innovations of tomorrow. These companies are... Read More

BOSTON & LAUSANNE, Switzerland / Mar 01, 2023 / Business Wire / SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced a new partnership with QIAGEN N.V. (NYSE: QGEN) that will pair QIAseq reagent technology with the SOPHiA DDM ™ platform to enhance tumor analysis through next-generation sequencing (NGS). The partnership will allow customers to order QIAseq panels that can be... Read More

BOSTON & LAUSANNE, Switzerland / Feb 28, 2023 / Business Wire / SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced that Synergy Oncology, part of Synergy Laboratories, a full-service diagnostic laboratory based in Mobile, Alabama, will use SOPHiA DDM™ to develop a new cancer profiling solution. The combination of technology from Synergy Oncology and SOPHiA GENETICS will... Read More

BOSTON & LAUSANNE, Switzerland / Feb 23, 2023 / Business Wire / SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced it will release its financial results for the fourth quarter and full year of fiscal 2022 before U.S. markets open on Tuesday, March 7, 2023. SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at... Read More

BOSTON & LAUSANNE, Switzerland / Feb 13, 2023 / Business Wire / SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a leading cloud-native global data-sharing network and health analytics platform, is partnering with AstraZeneca (LSE/STO/Nasdaq: AZN) to apply their multimodal technology and expertise to the biopharmaceutical company’s oncology portfolio. The multimodal approach will go beyond a single data modality, combining... Read More

SOPHiA GENETICS™ (Nasdaq: SOPH), a cloud-native software company in the healthcare space, has entered an agreement with Memorial Sloan Kettering Cancer Center (MSK) to offer clinicians and researchers new solutions to expand their testing and analytical capabilities. This includes incorporating proprietary Comprehensive Genomic Panel (CGP) sequencing tests such as MSK-ACCESS ® , which will be commercialized by SOPHiA... Read More

SOPHiA GENETICS SA (NASDAQ: SOPH) today announced that Dr. Jurgi Camblong, Chief Executive Officer and Co-Founder, is scheduled to present at the J.P. Morgan 2023 Healthcare Conference on Tuesday, January 10, 2023, at 8:15 a.m. PST in San Francisco. Live, listen-only webcasts of this presentation can be accessed by visiting the Investors section of the SOPHiA GENETICS website at ir.sophiagenetics.com . A replay of the... Read More